+44 20 8123 2220
info@marketpublishers.com

Melanoma [2016]: Bulletin #2

https://marketpublishers.com/r/M41AFD751E2EN.html
Date: May 2017
Pages: 0
Price: US$ 1,045.00 (Single User License)
ID: M41AFD751E2EN

Abstracts

This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Array BioPharma announcing that it has withdrawn its New Drug Application (NDA) in the US seeking approval of binimetinib for the treatment of neuroblastoma RAS viral oncogene homologue (NRAS) mutation-positive melanoma; NewLink Genetics reporting positive interim results from a Phase II study evaluating its IDO pathway inhibitor, indoximod, in combination with Keytruda (pembrolizumab); OncoSec Medical announcing data from a Phase II study assessing the combination of its investigational intratumoral therapy, ImmunoPulse IL-12, with Keytruda (pembrolizumab) in metastatic melanoma patients who are not expected to respond to anti-PD-1 agents.

Business Questions

Was the decision to withdraw the NDA for binimetinib as monotherapy in NRAS melanoma the right one?

Does binimetinib have a future in NRAS melanoma?

Is there room for the market to accommodate another BRAF and MEK inhibitor combination therapy to treat BRAF-positive melanoma?

If approved what will binimetinib/encorafenib’s main competitors be, and what setting(s) will it be used in?

How do KOLs view current data from the indoximod/Keytruda programme?

If approved, how likely is indoximod/Keytruda to impact nivolumab?

+44 20 8123 2220
info@marketpublishers.com

Is the rationale behind ImmunoPulse IL-12/Keytruda’s use in metastatic melanoma patients, who are not expected to respond to anti-PD-1 agents, justified?

How do KOLs view ImmunoPulse IL-12/Keytruda’s safety and efficacy?

What are the challenges facing the successful commercialisation of ImmunoPulse IL-12/Keytruda and what direction should development go in?

What other recent developments are of interest?

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Melanoma [2016]: Bulletin #2
Product link: https://marketpublishers.com/r/M41AFD751E2EN.html
Price: US$ 1,045.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/M41AFD751E2EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970